Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126034461 | 12603446 | 1 | I | 20160722 | 20160722 | 20160728 | 20160728 | EXP | JP-PFIZER INC-2016359011 | PFIZER | 40.00 | YR | M | Y | 0.00000 | 20160728 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126034461 | 12603446 | 1 | PS | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 37.5 MG, DAILY | 20699 | 37.5 | MG | PROLONGED-RELEASE CAPSULE | |||||||
| 126034461 | 12603446 | 2 | SS | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 225 MG, UNK | 20699 | 225 | MG | PROLONGED-RELEASE CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126034461 | 12603446 | 1 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126034461 | 12603446 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126034461 | 12603446 | Intentional self-injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126034461 | 12603446 | 1 | 201603 | 2016 | 0 | |
| 126034461 | 12603446 | 2 | 2016 | 0 |